Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2021-10-16 / Eur J Cancer 2021 Oct;158:123-132Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability
/in Curcuma, International Publications /von 2021-10-14 / Biomedicines 2021 Oct;9(10)Curcuma as an adjuvant in colorectal cancer treatment
/in Curcuma, International Publications /von 2021-10-09 / Life Sci 2021 Dec;286:120043Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2021-10-05 / Front Immunol 2021;12:721830Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2021-10-04 / Gene Ther 2023 Feb;30(1-2):64-74
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution